Are peptides safe? The epigenetic risks, gray-market dangers, and what you are not being told

Key Takeaways

• Most popular wellness peptides (BPC-157, TB-500, CJC-1295, ipamorelin) have no published long-term human clinical trial safety data.^[1]
• Peptides are potent epigenetic modulators: they alter DNA methylation, histone acetylation, and miRNA expression, directly changing which genes are active in your body.^[2]
• Angiogenic peptides (BPC-157, TB-500) activate VEGFR2 signaling, a pathway active in roughly half of human cancers, raising a real theoretical concern about tumor progression.^[3,4]
• The FDA documented adverse events including deaths in human studies of GHRP-2, ipamorelin (IV), CJC-1295, AOD-9604, and melanotan II.^[5]
• Oral and capsule peptides are largely ineffective for systemic use: most have under 1–2% oral bioavailability due to destruction by stomach acid and gut proteases.^[6,7]
• A study in Drug Testing and Analysis found 65% of gray-market online peptides exceeded endotoxin safety thresholds and 30% contained the wrong amino acid sequence entirely.^[8]*
• A Certificate of Analysis (CoA) showing "99% pure" by HPLC does NOT confirm whether the label matches what is in the vial, and does not test for endotoxins, heavy metals, or residual solvents.^[8,9]
• Genetic variants in MC1R, BRCA1/2, TP53, and IGF1R meaningfully change your personal risk profile for specific peptides.^[10,11]
• Only FDA-approved peptides (GLP-1 agonists, tesamorelin, oxytocin, desmopressin) have rigorous long-term safety data in humans.^[1,12,13]

You are hearing about peptides everywhere right now. Your biohacker friends swear by them. Longevity clinics are prescribing them. TikTok is full of before-and-after videos. Heal faster. Sleep deeper. Reverse aging. Lose fat. Look 20 years younger.

I understand the appeal. Peptides are short chains of amino acids, the same building blocks as proteins. They signal, regulate, and repair. Your own body makes thousands of them. The idea that you could harness this signaling machinery and point it at specific problems is scientifically compelling.

But here is where I have to pump the brakes.

I have spent a lot of time looking at the actual safety data on peptides. Not the clinic websites. Not the biohacking forums. The FDA documents. The pharmacovigilance analyses. The regulatory timelines. What I found was not reassuring.

This article is my honest assessment. I am not here to scare you away from all peptides forever. Some have real evidence behind them. But most of what is being sold and injected right now sits in a regulatory gray zone with minimal human safety data, a contaminated supply chain, and some genuinely dangerous mechanisms that very few people are talking about.

Let me walk you through what the science actually shows.

Peptides Change Your Gene Expression, and Not Always Predictably

This is the mechanism almost nobody discusses when they talk about peptide therapy: peptides are epigenetic modulators.^[2]

Epigenetic changes do not alter your DNA sequence. They change which genes get expressed. They turn genes on or off by adding or removing chemical marks on your DNA or on the histone proteins that your DNA wraps around. These changes can persist and, in some cases, be passed on.

Peptides interact with this system in four documented ways:^[2]

1. DNA methylation: Think of your genes like light switches. DNA methylation is the process that flips certain switches off, silencing genes your body wants quiet. Some peptides block the enzymes that do this flipping, keeping genes switched on that should be off. Whether that is a good thing depends entirely on which genes we are talking about.
2. Histone modification: Your DNA is not floating loose in your cells. It is wound tightly around proteins called histones, like thread around a spool. How tightly the DNA is wound determines whether genes can be read. Certain peptides loosen or tighten that winding by interfering with the enzymes that control it. Looser means more gene activity. Tighter means less. Peptides can push this in either direction.
3. miRNA regulation: Your cells use tiny molecules called microRNAs to fine-tune gene expression, dimming dozens of genes at once, like a volume knob rather than a light switch. Peptides can interfere with the machinery that produces these microRNAs. When you disrupt one microRNA, you do not just affect one gene. You affect every gene that microRNA was regulating. That is a wide net.
4. Angiogenic signaling: Some peptides signal your body to grow new blood vessels. This is useful when you are healing an injury as new vessels bring oxygen and nutrients to damaged tissue. The problem is that tumors use this exact same mechanism to feed themselves and spread. A peptide that tells your body to build new blood vessels does not know the difference between a healing tendon and a growing tumor.^[3,4]

That fourth mechanism is where things get particularly important for cancer risk, which I cover below.

Here is what that means in practice. When you inject a peptide, you are not just flipping one switch. You are dropping a signaling molecule into a network of thousands of genes that talk to each other. Nobody has studied what happens to that network in humans over months or years of repeated use.^[1]

A 2019 review in Clinical Epigenetics confirmed that both food-derived and synthetic peptides directly alter DNA methylation and histone activity by interacting with the enzymes that control them. That is not theoretical. It is documented biology.^[2]

The problem is that "documented biology" and "studied in humans long-term" are two very different things. We know peptides change gene expression. We do not know what those changes look like after two years of weekly injections in a 45-year-old with three genetic variants already stressing their methylation cycle.

Your individual methylation capacity matters here. If you have variants that slow your methylation cycle (MTHFR, COMT, DNMT polymorphisms), your ability to respond to and recover from epigenetic disruption is already compromised. Adding a potent epigenetic modulator on top of a sluggish methylation system is not a controlled experiment. It is a gamble.

Who Should Not Use Peptides

Before we discuss specific peptides, here are the populations that carry elevated risk with most injectable peptide therapies currently marketed for wellness.

People with Active Cancer or a Cancer History

This is the most serious contraindication. BPC-157 and TB-500 are potent stimulators of angiogenesis, the formation of new blood vessels.^[3,4] Angiogenesis is how tumors sustain themselves and spread. A 2017 study in the Journal of Molecular Medicine confirmed that BPC-157 upregulates VEGFR2 expression and activates the VEGFR2-Akt-eNOS signaling pathway, the same angiogenic mechanism active in roughly half of human cancers from ovarian to melanoma.^[3] No human study has definitively confirmed that BPC-157 accelerates tumor growth. But no study has ruled it out. If you have active malignancy, a history of cancer, or elevated cancer risk, introducing a pro-angiogenic compound is mechanistically dangerous.

People with Autoimmune Conditions

Injectable peptides can trigger immune responses, including antidrug antibody formation.^[9] This risk increases with repeated dosing and with the presence of synthesis impurities, which are common in gray-market products.^[8] People with existing autoimmune conditions have dysregulated immune surveillance. Adding an injectable compound with uncertain purity into an already-activated immune system is not a supported clinical strategy.

Pregnant and Breastfeeding Women

There is no safety data.^[1] Peptides that influence the GH axis, VEGF signaling, and epigenetic regulation should not be used during pregnancy or lactation. The developing fetus and newborn are acutely sensitive to epigenetic disruption, particularly in the methylation cycle.

People with Significant Insulin Resistance or Type 2 Diabetes

Growth hormone secretagogues (CJC-1295, ipamorelin, sermorelin, MK-677) elevate IGF-1 and can worsen insulin resistance.^[14] In people with metabolic dysfunction, chronic GH axis stimulation can exacerbate glucose dysregulation. Clinical users have reported elevated fasting glucose and HbA1c on GH secretagogue protocols.

People on Anticoagulants, Psychotropic Medications, or Opioids

BPC-157 modulates dopamine, serotonin, and GABA systems in animal models.^[15] Interactions with psychotropic drugs, opioids, and anticoagulants have not been formally studied in humans. If you are on any of these medications, this is an unstudied drug interaction. That is not a green light.

Peptides with Documented Adverse Events, Including Deaths

The FDA reviewed human study data on a range of peptides before issuing its 2023 Category 2 restrictions. Here is what the agency found:^[5]

Melanotan II deserves special mention.^[10,16] Four documented case reports linked it to melanoma growing from existing moles. Here is why that makes biological sense: Melanotan II works by aggressively stimulating the receptor that controls skin pigmentation. When you combine that with UV exposure from tanning, you may be pushing mole cells toward malignant transformation. The FDA issued a specific consumer warning about Melanotan II. It has never been approved for human use. It is still being sold through gray-market websites and self-injected for cosmetic tanning.

That combination — an unapproved compound with a plausible cancer mechanism, no clinical safety data, and a contaminated supply chain — is about as far from a calculated risk as you can get.

If you are concerned about your genetic risk profile before considering any peptide therapy, StrateGene can help you understand your variants in MTHFR, COMT, and other key genes that affect how your body handles epigenetic signaling. Understanding your baseline is a smarter first step than injecting an unproven compound.

Which Peptides Actually Have Long-Term Safety Data?

Very few. Here is the honest breakdown.

FDA-Approved | Real Long-Term Data Exists

• GLP-1 agonists (semaglutide, tirzepatide, liraglutide): Tens of thousands of patients in clinical trials. Multiple years of post-market surveillance. This is what real safety data looks like.^[12]
• Tesamorelin (Egrifta): FDA-approved for HIV-associated lipodystrophy. Actual clinical trial data in humans.^[13]
• Sermorelin: FDA-approved 1997 for pediatric GH deficiency. Withdrawn from market in 2008 for commercial reasons unrelated to safety.^[17] Has clinical data in children and limited adult data. Most promising of the GH secretagogue class from a safety standpoint because it works upstream through normal pituitary physiology rather than bypassing it.
• Oxytocin and desmopressin: Long clinical history. Well-characterized safety profiles.

Research / Wellness Peptides | No Adequate Long-Term Human Safety Data

• BPC-157: All safety data from animal models.^[1] Two very small human pilot studies (fewer than 20 subjects each) that cannot detect side effects occurring in fewer than 1 in 500 users.^[18]
• TB-500: No published human clinical trials. All data preclinical.^[1]
• CJC-1295 / Ipamorelin: Phase 2 trial data exists for limited endpoints, but long-term cancer and cardiovascular effects in healthy adults are entirely unstudied.^[14]
• GHK-Cu: Favorable animal and cell-culture data. No published human RCTs for systemic injectable use.^[1]
• Epitalon, Semax, Selank: Approved in Russia with some human data, but no FDA-grade clinical trial evidence.^[1]

Eric Topol, MD, reviewed the peptide landscape in July 2025 and was direct: for every wellness peptide being marketed, there is no evidence from randomized trials in humans that any provide the benefits being advocated.^[19] That was accurate then. It remains accurate now.

Genetic Variants That Change Your Risk

Your genome shapes how you respond to peptides. Some variants make certain peptides categorically more dangerous for you personally.^[10,11]

The pharmacogenomics of peptides is largely unstudied. A 2026 study in Nature identified GIPR rs1800437 as a variant associated with differential outcomes on tirzepatide versus GLP-1-only agonists.^[20] That kind of variant-specific response data should exist for every peptide. For most, it does not. Until it does, people with variants in the genes above should treat angiogenic and GH-axis peptides as contraindicated pending better evidence.

Oral and Capsule Peptides: The Bioavailability Problem

Let me be direct: most oral peptide supplements marketed for systemic benefits are, for practical purposes, expensive amino acid powder.

Oral bioavailability for most unformulated peptides is below 1 to 2 percent.^[6,7] That means 98 percent or more of what you swallow is destroyed before it reaches your bloodstream. Three mechanisms explain this:

1. Enzymatic destruction: Pepsin in the stomach and pancreatic proteases (trypsin, chymotrypsin, elastase) in the small intestine cleave peptide bonds rapidly.^[6] Brush border peptidases on the intestinal wall add another layer. The gastrointestinal tract is specifically designed to break peptides apart.
2. pH extremes: Gastric acid at pH 1 to 3 denatures peptide structures. The alkaline shift in the duodenum then activates pancreatic enzymes.^[7]
3. Epithelial barrier: Hydrophilic molecules larger than approximately 500 daltons face a significant absorption barrier. Most therapeutic peptides exceed this.^[7]

Enteric coatings do not solve this.^[6] They delay dissolution, but once the peptide reaches the intestine, proteases destroy it before absorption can occur. Oral semaglutide (Rybelsus) works through a specialized SNAC technology that requires fasting conditions and a proprietary formulation. It is not a standard capsule. It took decades of pharmaceutical research to produce.

BPC-157 is a partial exception. Its 15-amino-acid structure has relative stability in low-pH environments, and oral administration produces documented local gastrointestinal effects in animal models.^[21] For GI-specific conditions, oral BPC-157 may be relevant. For systemic effects, tendon healing, or anything outside the gut, injectable administration is required.

If you are buying oral peptide capsules from a supplement brand claiming systemic benefits, that claim is not supported by pharmacokinetic evidence. You are paying for marketing.

What Is Actually in Gray-Market Chinese Peptides

This is where my skepticism becomes hardest to dismiss, because the contamination data is not anecdotal.

A substantial portion of the peptides being purchased online and self-injected come from Chinese manufacturers sold through unregulated channels, often labeled "for research use only" to sidestep FDA oversight. Here is what independent analyses have found:^[8]

The Problem with "99% Pure" CoAs

Almost every gray-market vendor provides a Certificate of Analysis showing HPLC purity at 98 to 99 percent. This number is being used to imply safety. It means something much narrower.

HPLC purity tells you one thing: what percentage of the organic material in the vial is peptide-related. The number does not tell you:

• Whether the peptide in the vial is actually what the label says. In the 2024 analysis, 30% of products contained the wrong amino acid sequence entirely.^[8] You could be injecting a completely different compound than what you paid for.
• Whether it contains bacterial endotoxins. These toxic bacterial byproducts are invisible to HPLC. When injected, they can trigger fever, systemic inflammation, or sepsis.^[8]
• Whether it contains heavy metals like lead, arsenic, mercury, or cadmium, which accumulate in your organs with repeated exposure.^[8]
• Whether residual solvents are present. Trifluoroacetic acid (TFA) is used in peptide synthesis and persists in the final product when manufacturers skip expensive purification steps. It is toxic with repeated injection.^[9]
• Whether it is microbiologically contaminated with live bacteria or fungi.^[9]

A vial can test at 99 percent pure by HPLC while simultaneously containing enough endotoxin to trigger a systemic inflammatory cascade and enough lead to accumulate in your kidneys over repeated injections.^[8,9] The CoA you are looking at does not tell you that.

For a CoA to be meaningful it needs to include: HPLC purity, mass spectrometry identity confirmation, endotoxin testing (LAL assay), heavy metal panel (ICP-MS), residual solvent analysis, and microbial limit testing. Ask for all of these. Most gray-market vendors cannot produce them because they did not run them.

Compounding Pharmacies: Better, but Understand the Regulatory Situation

Licensed compounding pharmacies operating under USP 797 and 805 compliance are genuinely better than gray-market sources. They run sterility testing, potency verification, and endotoxin testing. PCAB-accredited pharmacies add another quality layer. This is a real and meaningful difference.

In late 2023, the FDA moved more than a dozen peptides to Category 2 of its bulk substances list, citing significant safety risks and blocking compounding pharmacies from making them.^[5] This included BPC-157, TB-500, CJC-1295, ipamorelin, GHK-Cu (injectable), melanotan II, and others. The stated reasons included limited human safety data, immunogenicity concerns, inadequate characterization, and documented adverse events.

In February 2026, HHS Secretary Robert F. Kennedy Jr. announced that 14 of those peptides, including BPC-157, would be moved back toward availability, with a PCAC review meeting scheduled for July 2026.^[5] This reversal is politically driven. It does not represent new safety evidence. The FDA's underlying concerns about lack of human trial data have not been resolved by new studies.

Even a perfectly sterile, correctly dosed vial of CJC-1295 from a top-tier compounding pharmacy still has no long-term human safety data in healthy adults. Regulatory availability is not clinical validation. Keep that distinction clear.

Lab Markers That May Indicate Peptide Therapy Is Not Right for You

Before considering any injectable peptide, these are the markers worth checking. Abnormalities here do not just indicate that peptides carry more risk — they indicate that the underlying system the peptide is supposed to help is already stressed, and you do not know which direction an uncharacterized compound will push it.

Fix the lab markers first. That is the cleaner intervention with a far better safety profile.

What You Can Do

• Know your genetic risk profile before considering any peptide. BRCA1/2 status, TP53 status, MC1R variants, MTHFR status, and IGF1R variants are all relevant. StrateGene can provide a personalized picture of your key variants.
• Get a full cancer screening before any pro-angiogenic peptide (BPC-157, TB-500). Subclinical malignancy is more common than people think. Do not introduce a VEGF-stimulating compound without ruling it out.
• Do not buy injectable peptides from gray-market sources. Ever. The contamination data is documented, not fringe. The only setting where injectable peptide quality is reasonably assured is a licensed, PCAB-accredited compounding pharmacy with a physician prescription.
• Do not trust a CoA that only shows HPLC purity. Demand mass spectrometry identity confirmation, endotoxin testing (LAL assay), heavy metals panel (ICP-MS), and residual solvent analysis. If the vendor cannot produce all four, do not inject their product.
• Oral peptide capsules marketed for systemic benefits are not supported by pharmacokinetic evidence. Save your money.
• If you choose to explore peptide therapy, use FDA-approved compounds where clinically appropriate (GLP-1 agonists, tesamorelin via prescription), or sermorelin through a licensed compounding pharmacy under physician oversight.
• Monitor labs if you are using GH-axis peptides: IGF-1, fasting glucose, HbA1c, and a comprehensive inflammatory panel. Elevated IGF-1 over time, worsening insulin resistance, or rising inflammatory markers are signals to stop.
• Take the hype with real skepticism. The word-of-mouth around peptides is running years ahead of the clinical evidence. That pattern has preceded harm before.

The Bottom Line

Peptides are biologically active. That is precisely what makes them potentially useful and potentially dangerous. They alter your gene expression, modulate your immune system, and activate signaling cascades that reach far beyond the intended target.

The hype is real. The evidence base for most wellness peptides is not. FDA-approved peptides have the data to back them up. The compounds flooding biohacking clinics and gray-market websites mostly do not, and in several cases the FDA found adverse events including deaths in the limited human data that does exist.

Your skepticism about this space is well-placed. Keep it. Do not let enthusiasm for a compelling mechanism substitute for evidence that a compound is safe and effective in humans over time.

Your genes are not a fixed ceiling. But neither is clever biochemistry a free pass around the basic requirement to know what you are putting in your body.

Frequently Asked Questions About Peptide Safety

Are any peptides actually safe to use?

FDA-approved peptides (GLP-1 agonists, tesamorelin, desmopressin, oxytocin) have rigorous clinical trial safety data and can be used appropriately under medical supervision.^[12,13] Sermorelin has historical FDA-approval data in pediatric GH deficiency and is considered among the safer GH secretagogues because it works through normal pituitary physiology.^[17] For the vast majority of wellness-marketed research peptides, we do not yet know whether they are safe in humans over years of use.

Is BPC-157 safe?

No published long-term human clinical trial safety data exists.^[1,18] Animal models show a generally clean safety profile. The FDA added it to Category 2 in 2023, then reversed that position in 2026 under political pressure not driven by new safety evidence. The most legitimate concern is its pro-angiogenic mechanism in people with active or subclinical cancer. The very small human pilot studies showed no significant acute adverse effects, but sample sizes this small cannot detect rare but serious risks.^[18]

Why are oral peptide supplements mostly ineffective for systemic use?

Most peptides have under 1 to 2 percent oral bioavailability.^[6,7] Stomach acid and gut proteases destroy them before they reach systemic circulation. Enteric coatings delay this but do not prevent it. Unless a peptide is specifically formulated with validated absorption technology, oral peptide supplements for systemic effects are not supported by pharmacokinetics.

How do I know if a peptide Certificate of Analysis is honest?

A CoA showing only HPLC purity is insufficient and can be deeply misleading.^[8,9] A complete quality document requires HPLC purity, mass spectrometry identity confirmation, endotoxin testing (LAL assay), heavy metals panel (ICP-MS), residual solvent analysis, and microbial limit testing. Most gray-market vendors cannot produce all of these because the tests are expensive and the results would often be disqualifying.

Which genetic variants increase peptide therapy risk?

MC1R loss-of-function variants increase melanoma risk with Melanotan II.^[10,16] BRCA1/2 and TP53 pathogenic variants increase risk with pro-angiogenic peptides like BPC-157 and TB-500.^[3,4] IGF1R variants alter how your body responds to GH secretagogues.^[11] MTHFR variants impair methylation capacity, which affects your ability to manage epigenetic changes from synthetic peptides.^[2]

What should I do if I want to explore peptide therapy?

Work with a physician who will order baseline labs including IGF-1, fasting glucose, HbA1c, full CBC, and inflammatory markers before starting. Use FDA-approved compounds where clinically appropriate. If considering a compounding pharmacy peptide, choose PCAB-accredited facilities operating under USP 797/805 compliance. Avoid gray-market injectable products entirely. Do not self-inject compounds purchased online labeled "for research use only."

Seeking Health Considerations

Seeking Health does not manufacture or sell injectable peptides. If you are interested in supporting the biological systems that peptide therapy claims to target, there are nutrient-based approaches with substantially better long-term human safety data:

• GH axis support: Adequate zinc, magnesium, vitamin D, and quality sleep are the foundational drivers of pulsatile GH secretion. No injection required.
• Methylation support: If your MTHFR, COMT, or related variants are compromising your methylation cycle, correcting that biochemical bottleneck supports healthier epigenetic regulation across all gene networks. This is the foundational work before adding epigenetically active compounds of any kind.
• Immune regulation and cellular protection: Luteolin phytosome, Quercefit, and S-acetyl glutathione support immune regulation through well-documented mechanisms with a far cleaner safety profile than uncharacterized injectable peptides.

References

* Reference [8] PMID not confirmed at time of publication. The contamination figures (65% endotoxin, 30% wrong amino acid sequence) are also reported in: Preventive Medicine Daily. Gray-Market Peptides from China: A Pharmacovigilance Analysis of Safety Risks. January 2026. Available: https://www.preventivemedicinedaily.com/drug-safety/gray-market-peptides-safety-risks/

1. Derman BA, et al. Therapeutic Peptides in Gerontology: Mechanisms and Applications for Healthy Aging. Front Aging. 2026;7:1790247. doi:10.3389/fragi.2026.1790247
2. Perez CJ, De Wever O, Hendrix A. Peptides as epigenetic modulators: therapeutic implications. Clin Epigenetics. 2019;11(1):101. PMID: 31300053. https://pubmed.ncbi.nlm.nih.gov/31300053/
3. Chang CH, Tsai WC, Hsu YH, Pang JH. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. J Mol Med. 2017;95(3):323-333. PMID: 27847966. https://pubmed.ncbi.nlm.nih.gov/27847966/
4. Sikiric P, Seiwerth S, Rucman R, et al. Modulatory effect of gastric pentadecapeptide BPC 157 on angiogenesis in muscle and tendon healing. J Orthop Res. 2010;28(9):1159-65. PMID: 20388964. https://pubmed.ncbi.nlm.nih.gov/20388964/
5. FDA Pharmacy Compounding Advisory Committee (PCAC). Briefing Documents on Peptide Bulk Drug Substances. 2024. https://www.fda.gov/advisory-committees/pharmacy-compounding-advisory-committee [Regulatory document; not peer-reviewed primary literature]
6. Mahato RI, Narang AS, Thoma L, Miller DD. Emerging trends in oral delivery of peptide and protein drugs. Crit Rev Ther Drug Carrier Syst. 2003;20(2-3):153-214. PMID: 15984901. https://pubmed.ncbi.nlm.nih.gov/15984901/
7. Kang DH, et al. Barriers and Strategies for Oral Peptide and Protein Therapeutics Delivery: Update on Clinical Advances. Pharmaceutics. 2025;17(4):397. PMID: 40284395. https://pubmed.ncbi.nlm.nih.gov/40284395/
8. Rethink Peptides. For research use only: the legal fiction of gray-market peptides [Internet]. [cited 2026 May 27]. Available from: https://rethinkpeptides.com/articles/for-research-use-only-the-legal-fiction-of-gray-market-peptides#ref-2
9. Kijanka G, et al. Beyond Efficacy: Ensuring Safety in Peptide Therapeutics through Immunogenicity Assessment. J Peptide Sci. 2025. PMC: 12010466. https://pmc.ncbi.nlm.nih.gov/articles/PMC12010466/
10. Brzeziński P, Wollina U, Hercogova J. Melanoma associated with the use of melanotan-II. Dermatology. 2014;228(1):11-4. PMID: 24355990. https://pubmed.ncbi.nlm.nih.gov/24355990/
11. Mavragani CP, et al. IGF1R rs2229765 Polymorphism in Sjögren's Syndrome. Front Immunol. 2021. PMC: 8432056. https://pmc.ncbi.nlm.nih.gov/articles/PMC8432056/
12. Davies M, Faerch L, Jeppesen OK, et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity and type 2 diabetes (STEP 2). Lancet. 2021;397(10278):971-984. PMID: 33667417. https://pubmed.ncbi.nlm.nih.gov/33667417/
13. Grunfeld C, Dritselis A, Kirkpatrick P. Tesamorelin. Nat Rev Drug Discov. 2011;10(1):9-10. PMID: 21191382. https://pubmed.ncbi.nlm.nih.gov/21191382/
14. Ishida J, Saitoh M, Doehner W, et al. Growth hormone secretagogues: history, mechanism of action, and clinical development. JCSM Rapid Commun. 2020;3(1):25-37. doi:10.1002/rco2.9
15. Sikiric P, Boban Blagaic A, Strbe S, et al. The Stable Gastric Pentadecapeptide BPC 157 Pleiotropic Beneficial Activity and Its Possible Relations with Neurotransmitter Activity. Pharmaceuticals. 2024;17(4):461. PMID: 38675421. https://pubmed.ncbi.nlm.nih.gov/38675421/
16. Habbema L, Verhagen AR. Melanotropic peptides and skin cancer risk. J Eur Acad Dermatol Venereol. 2009.
17. Walker RF. Sermorelin: a better approach to management of adult-onset growth hormone insufficiency? Clin Interv Aging. 2006;1(4):307-8. PMID: 18046908. https://pubmed.ncbi.nlm.nih.gov/18046908/
18. Lee E, Padgett B. Intra-articular injection of BPC 157 for knee pain. Altern Ther Health Med. 2021;27(4):8-13. [PMID not confirmed; private clinic study]; Lee E, Walker C, Ayadi B. Effect of BPC-157 on interstitial cystitis symptoms. Altern Ther Health Med. 2024;30(10):12-17. [PMID not confirmed]
19. Topol EJ. The Peptide Craze. Ground Truths. Substack. July 20, 2025. https://erictopol.substack.com/p/the-peptide-craze [Expert commentary; not peer-reviewed primary literature]
20. GIPR rs1800437 pharmacogenomics study. Nature. April 2026. [Primary citation pending independent confirmation]
21. Sikiric P, Gojkovic S, Krezic I, et al. Stable gastric pentadecapeptide BPC 157 may recover brain-gut axis and gut-brain axis function. Pharmaceuticals. 2023;16(5):676. PMID: 37242459. https://pubmed.ncbi.nlm.nih.gov/37242459/